WHO – Page 28 – Pharma.Tips

Uncontrolled SOP changes during scale-up – CAPA framework to prevent recurrence

Managing Uncontrolled SOP Changes During Scale-Up: A CAPA Framework Operational challenges often arise during the scale-up of pharmaceutical manufacturing processes. One major concern is the occurrence of uncontrolled changes in…

Inconsistent GMP interpretation during internal audit – how to rebuild GMP maturity

Addressing Inconsistent GMP Interpretation during Internal Audits to Elevate GMP Maturity Inconsistent interpretations of Good Manufacturing Practices (GMP) during internal audits represent a critical challenge for pharmaceutical manufacturers aiming for…

Inconsistent GMP interpretation during regulatory inspection – evidence package for inspection defense

“`html Addressing Inconsistent GMP Interpretation During Regulatory Inspections: An Actionable Playbook Inconsistent interpretations of Good Manufacturing Practices (GMP) during regulatory inspections can lead to significant challenges for pharmaceutical manufacturers. Oftentimes,…

Weak management oversight during technology transfer – evidence package for inspection defense

Addressing Weak Management Oversight During Technology Transfer: A Playbook for Effective Defense In the pharmaceutical manufacturing landscape, weak management oversight during technology transfer can lead to significant quality and compliance…

Batch documentation gaps during routine manufacturing – CAPA framework to prevent recurrence

Addressing Batch Documentation Gaps in Routine Manufacturing: A Practical CAPA Framework Batch documentation gaps can often lead to regulatory scrutiny during inspections and audits, potentially jeopardizing your compliance status. This…

Batch documentation gaps during technology transfer – CAPA framework to prevent recurrence

Addressing Batch Documentation Gaps During Technology Transfer: A Comprehensive CAPA Framework Batch documentation gaps during technology transfer can pose significant risks to quality and compliance in pharmaceutical manufacturing. These gaps…

Poor change control discipline during routine manufacturing – CAPA framework to prevent recurrence

Addressing Poor Change Control Practices in Routine Manufacturing: A Comprehensive CAPA Playbook In pharmaceutical manufacturing, the integrity of the change control process is critical. Poor change control discipline during routine…

Weak management oversight during internal audit – FDA/EMA inspection citation risk

Addressing Weak Management Oversight in Internal Audits to Ensure Compliance and Inspection Readiness The pharmaceutical industry is under immense scrutiny from regulatory bodies such as the FDA, EMA, and MHRA.…

Inconsistent GMP interpretation during scale-up – evidence package for inspection defense

Addressing Inconsistent GMP Interpretations During Scale-Up for Inspection Readiness In the high-stakes environment of pharmaceutical manufacturing, inconsistent Good Manufacturing Practice (GMP) interpretations can lead to serious regulatory challenges, especially during…